Vlad C Sandulache1, John Hamblin1, Syeling Lai2,3, Todd Pezzi1, Heath D Skinner4, Numan A Khan1, Shayan M Dioun1, Christine Hartman5, Jennifer Kramer5, Elizabeth Chiao5, Xiaodong Zhou6, Jose P Zevallos1. 1. Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, Texas. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Houston Veterans Affairs Health Services Research and Development Center, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. 4. Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. 5. Department of Pathology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. 6. Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas.
Abstract
BACKGROUND: A significant fraction of oropharyngeal squamous cell carcinoma (SCC) cases is associated with traditional carcinogens; in these patients, treatment response and clinical outcomes remain poor. METHODS: We evaluated patient, tumor, and treatment characteristics for 200 veterans with oropharyngeal SCC treated at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) between 2000 and 2012. RESULTS: Most patients (77%) were white and heavy smokers. Twenty-seven patients required tracheostomy and 63 required gastrostomy placement during treatment. Overall survival (OS) at 5 years was 40%. Survival was impacted by T classification, treatment intensity, completion of treatment, and p16 tumor status. Almost 30% of patients were unable to complete a treatment regimen consistent with National Comprehensive Cancer Network (NCCN) guidelines. CONCLUSION: Oropharyngeal SCC in veterans is associated with traditional carcinogens and poor clinical outcomes. Despite heavy smoking exposure, p16 tumor status significantly impacts survival. Careful consideration must be given to improving treatment paradigms for this cohort given their limited tolerance for treatment escalation.
BACKGROUND: A significant fraction of oropharyngeal squamous cell carcinoma (SCC) cases is associated with traditional carcinogens; in these patients, treatment response and clinical outcomes remain poor. METHODS: We evaluated patient, tumor, and treatment characteristics for 200 veterans with oropharyngeal SCC treated at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) between 2000 and 2012. RESULTS: Most patients (77%) were white and heavy smokers. Twenty-seven patients required tracheostomy and 63 required gastrostomy placement during treatment. Overall survival (OS) at 5 years was 40%. Survival was impacted by T classification, treatment intensity, completion of treatment, and p16tumor status. Almost 30% of patients were unable to complete a treatment regimen consistent with National Comprehensive Cancer Network (NCCN) guidelines. CONCLUSION: Oropharyngeal SCC in veterans is associated with traditional carcinogens and poor clinical outcomes. Despite heavy smoking exposure, p16tumor status significantly impacts survival. Careful consideration must be given to improving treatment paradigms for this cohort given their limited tolerance for treatment escalation.
Authors: Bruce H Haughey; Michael L Hinni; John R Salassa; Richard E Hayden; David G Grant; Jason T Rich; Simon Milov; James S Lewis; Murli Krishna Journal: Head Neck Date: 2011-01-31 Impact factor: 3.147
Authors: Martina A Broglie; Alex Soltermann; David Rohrbach; Sarah R Haile; Michael Pawlita; Gabriela Studer; Gerard F Huber; Holger Moch; Sandro J Stoeckli Journal: Head Neck Date: 2013-03-18 Impact factor: 3.147
Authors: Genevieve Andrews; Miriam Lango; Roger Cohen; Steven Feigenberg; Barbara Burtness; Ranee Mehra; Sidrah Ahmed; Nicos Nicolaou; John Gaughan; John A Ridge Journal: Head Neck Date: 2010-11-10 Impact factor: 3.147
Authors: Jimmy J Caudell; Robert D Hamilton; Kristen J Otto; Richard L Jennelle; Karen T Pitman; Srinivasan Vijayakumar Journal: Am J Clin Oncol Date: 2014-08 Impact factor: 2.339
Authors: Samuel J Gan; Kristina R Dahlstrom; Brandon W Peck; Wes Caywood; Guojun Li; Qingyi Wei; Mark E Zafereo; Erich M Sturgis Journal: Cancer Date: 2013-04-19 Impact factor: 6.860
Authors: V C Sandulache; Y L Lei; L E Heasley; M Chang; C I Amos; E M Sturgis; E Graboyes; E Y Chiao; N Rogus-Pulia; J Lewis; A Madabhushi; M J Frederick; A Sabichi; M Ittmann; W G Yarbrough; C H Chung; R Ferrarotto; Weiyuan Mai; H D Skinner; U Duvvuri; P Gerngross; A G Sikora Journal: Oral Oncol Date: 2019-10-22 Impact factor: 5.337
Authors: Steven Doerstling; David Winski; Evangelia Katsoulakis; Pankaj Agarwal; Pradeep J Poonnen; Jane L Snowdon; Gretchen P Jackson; Dilhan Weeraratne; Michael J Kelley; Vishal Vashistha Journal: J Cancer Res Clin Oncol Date: 2022-09-18 Impact factor: 4.322
Authors: Jose P Zevallos; Jennifer R Kramer; Vlad C Sandulache; Sean T Massa; Christine M Hartman; Angela L Mazul; Benjamin M Wahle; Sophie P Gerndt; Erich M Sturgis; Elizabeth Y Chiao Journal: Head Neck Date: 2020-09-12 Impact factor: 3.821
Authors: Peter A Richardson; Sagar Kansara; George G Chen; Anita Sabichi; Andrew G Sikora; Robert B Parke; Donald T Donovan; Elizabeth Chiao; Vlad C Sandulache Journal: Laryngoscope Investig Otolaryngol Date: 2018-08-09
Authors: J O Kemnade; H Elhalawani; P Castro; J Yu; S Lai; M Ittmann; A S R Mohamed; S Y Lai; C D Fuller; A G Sikora; V C Sandulache Journal: Sci Rep Date: 2020-01-14 Impact factor: 4.379
Authors: Luiz Paulo Kowalski; Max Moura de Oliveira; Rossana Veronica Mendoza Lopez; Diego Rodrigues Mendonça E Silva; Mauro Kazuo Ikeda; Maria Paula Curado Journal: Clinics (Sao Paulo) Date: 2020-04-06 Impact factor: 2.365
Authors: Vlad C Sandulache; David C Wilde; Erich M Sturgis; Elizabeth Y Chiao; Andrew G Sikora Journal: Laryngoscope Investig Otolaryngol Date: 2019-10-17
Authors: Hesham Elhalawani; Abdallah S R Mohamed; Baher Elgohari; Timothy A Lin; Andrew G Sikora; Stephen Y Lai; Abdelrahman Abusaif; Jack Phan; William H Morrison; G Brandon Gunn; David I Rosenthal; Adam S Garden; Clifton D Fuller; Vlad C Sandulache Journal: BMC Cancer Date: 2020-09-23 Impact factor: 4.430